Evidence map›Paper›PMID 40474296›Full record

ArticleBreast cancer research : BCR2025

Dissecting the tumor microenvironment in primary breast angiosarcoma: insights from single-cell RNA sequencing.

Peikai Ding, Shengbin Pei, Yi Zhai, Zheng Qu, Yazhe Yang, Xiaolong Feng, Qiang Liu, Xiangyu Wang, Wenxiang Zhang, Zhongzhao Wang and 3 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Peikai Ding *Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Shengbin Pei *Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Yi Zhai *Department of Oncology, Zibo Central Hospital, Zibo, Shandong, 255036, China.
Zheng Qu *Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Yazhe Yang *Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Xiaolong FengDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Qiang LiuDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Xiangyu WangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Wenxiang ZhangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Zhongzhao WangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Xiangyi KongDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. kongxiangyi@pumc.edu.cn.
Jing WangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. wangjing@cicams.ac.cn.
Yi FangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. fangyi@cicams.ac.cn.

Funding

National Natural Science Foundation of China No.82072940
6 · The paper itself

Abstract

backgroundAngiosarcoma, a rare and highly aggressive malignancy originating from vascular endothelial cells, is characterized by its rapid progression, high invasiveness, and poor prognosis. Due to the limited understanding of its tumor microenvironment (TME) and the absence of effective treatments, further research is essential to elucidate its pathogenic mechanisms and improve therapeutic strategies.

objectiveThis study aims to characterize the cellular heterogeneity and unique TME of primary breast angiosarcoma using single-cell RNA sequencing (scRNA-seq), to identify potential therapeutic targets and improve clinical outcomes.

methodsTumor samples were obtained from a patient with bilateral primary breast angiosarcoma and two patients with invasive breast cancer. Single-cell RNA sequencing (scRNA-seq) was conducted to capture the transcriptomic profiles of individual cells within the tumor samples. Following stringent quality control, a total of 31,771 cells were analyzed using comprehensive bioinformatics approaches. Cell populations were identified and classified into distinct cell types, and differential gene expression analysis was performed to explore key signaling pathways. Functional enrichment analysis was used to identify pathways related to tumor progression and immune evasion. Additionally, cell-cell communication networks were mapped to understand interactions within the TME, with a focus on pathways that may serve as therapeutic targets.

resultsThe scRNA-seq analysis revealed significant differences in the distribution of perivascular cells, fibroblasts, T cells, endothelial cells, and myeloid cells in breast angiosarcoma compared to invasive breast cancer. Key pathways enriched in angiosarcoma samples included growth factor binding, platelet-derived growth factor binding, and ribosome biogenesis, with abnormal expression of several ribosomal proteins. Notably, genes such as FAT4, KDR, FN1, and KIT were highly expressed in angiosarcoma endothelial cells, correlating with poor prognosis. Cell communication analysis highlighted the CXCL12-CXCR4 axis as a crucial mediator of the TME in angiosarcoma.

conclusionThis study provides critical insights into the TME of primary breast angiosarcoma, highlighting potential molecular targets and pathways for therapeutic intervention. These findings may inform the development of more effective treatment strategies for this rare and challenging tumor type.

Indexed as

Biomarkers, TumorBreast NeoplasmsHemangiosarcomaSingle-Cell AnalysisTumor MicroenvironmentCell CommunicationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisSequence Analysis, RNASignal TransductionTranscriptomeBiomarkers, TumorBreast angiosarcomaBreast cancerScRNA-seqTumor microenvironment

Identifiers

PMID40474296
PMCPMC12142952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.